CRVS241220P7000
- 2.55
- +0.11+4.51%
Corvus Pharmaceuticals Newsroom
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Falls After Early-stage Data for Eczema Therapy
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost
Express News | Corvus Pharmaceuticals Inc - Lowest Dose Level Cohorts Show Favorable Safety and Efficacy
Market-Moving News for December 18th
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Biggest Stock Movers Wednesday: COMM, HEI, and More
Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding
Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal
Express News | Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Individual Investors Account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Ownership, While Private Equity Firms Account for 16%
Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition With Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Attackers Targeting VPNs Account for 28.7 Percent of Ransomware Incidents in Q3 According to Corvus Insurance Cyber Threat Report
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.